Here we have shown, using complementary in vitro and in vivo functional assays, that inhibition of c-FLIP (FLIPi) overcomes resistance of breast cancer stem cells (bCSCs) to the anti-cancer agent TRAIL, resulting in the selective elimination of stem cell characteristics in all of the cell lines tested, independent of hormone receptor status. Here, NR4A1 is linked to breast carcinoma.